Taken together, we believe that substantial research is still required to illuminate the detailed mechanisms involved in lysine acetylation-mediated regulation of glioma malignancy that may ultimately lead to new and effective targeted therapies for glioma patients, and the use of LAR-subtype and LAR-signature are promising for further clinical applications and need more perspective evidence. The gene discussed is PTPRF; the disease is glioma.